https://www.selleckchem.com/pr....oducts/alflutinib-as
d to AMR and management (e.g. unnecessary psychological morbidity from infections that do not need treatment). There is a need to identify scalable tuberculosis screening strategies among high burden populations. The WHO has identified a non-sputum-based triage test as a development priority. We performed a diagnostic case-control study of point-of-care C-reactive protein (CRP) and Prototype-Xpert-MTB-Host-Response (Xpert-MTB-HR) assays in the context of a mass screening program for tuberculosis in two prisons in Bra
Like
Comment
Share
